Meng Xiao He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meng Xiao He has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Eliezer Mendel Van Allen
Broad Institute of MIT and Harvard, Cambridge, USA
22 shared publications - Sabrina Y. Camp
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
20 shared publications - Jett Crowdis
Dana-Farber Cancer Institute 2 Department of Medical Oncology Boston, Massachusetts
19 shared publications - Agnes Viale
Memorial Sloan Kettering Cancer Center
18 shared publications - Ahmet Dogan
Memorial Sloan Kettering Cancer Center, New York, NY
18 shared publications - Amy E. Webber
Bioinformatics Core, Memorial Sloan Kettering Cancer Center, New York, New York
18 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Genomically matched targeted therapies guided by MSK-IMPACT testing (n=22).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Genomically matched targeted therapies guided by MSK-IMPACT testing (n=22).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Clonality assessment of known oncogenic mutations in the female GCT cohort.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Clonality assessment of known oncogenic mutations in the female GCT cohort.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Patient demographic data for the female patients in the Extragonadal GCT cohort (both Make-an-IMPACT and internal MSK patients, n=16)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Patient demographic data for the female patients in the Extragonadal GCT cohort (both Make-an-IMPACT and internal MSK patients, n=16)
- Open Access
Single-cell epigenetic profiling reveals an interferon response-high program associated with BAP1 deficiency in kidney cancer
Renal cell carcinoma (RCC) is characterized by recurrent somatic mutations in epigenetic regulators, which stratify patients into clinically significant subgroups with distinct prognoses and treatment responses. However, the cell type-specific epigenetic landscape of RCC—broadly and in the context of these mutations—is incompletely understood. To investigate these open questions, we integrated single nucleus ATAC sequencing data from RCC tumors across four independent cohorts. In clear cell RCC tumors, we identified four shared malignant epigenetic programs related to angiogenesis, proximal tubule-like features, interferon (IFN) signaling, and one that lacked distinct genomic regions with increased accessibility. Among the mutated epigenetic regulators, BAP1 mutation exhibited the most significant impact on chromatin accessibility in tumor cells, and the associated epigenetic changes were linked to IFN response. We identify multiple potential sources of elevated IFN signaling in these lesions, such as increased immune infiltration and increased accessibility and expression of an IFN-associated ERV, ERV3-16A3_LTR. We find that the expression of ERV3-16A3_LTR may itself be a negative prognostic biomarker in ccRCC. Our findings highlight the convergence of malignant epigenetic programs across ccRCC tumors and suggest that BAP1 loss, potentially through ERV3-16A3_LTR dysregulation, is associated with an IFN response-high epigenetic program.
Open AccessSingle-cell epigenetic profiling reveals an interferon response-high program associated with BAP1 deficiency in kidney cancer
Renal cell carcinoma (RCC) is characterized by recurrent somatic mutations in epigenetic regulators, which stratify patients into clinically significant subgroups with distinct prognoses and treatment responses. However, the cell type-specific epigenetic landscape of RCC—broadly and in the context of these mutations—is incompletely understood. To investigate these open questions, we integrated single nucleus ATAC sequencing data from RCC tumors across four independent cohorts. In clear cell RCC tumors, we identified four shared malignant epigenetic programs related to angiogenesis, proximal tubule-like features, interferon (IFN) signaling, and one that lacked distinct genomic regions with increased accessibility. Among the mutated epigenetic regulators, BAP1 mutation exhibited the most significant impact on chromatin accessibility in tumor cells, and the associated epigenetic changes were linked to IFN response. We identify multiple potential sources of elevated IFN signaling in these lesions, such as increased immune infiltration and increased accessibility and expression of an IFN-associated ERV, ERV3-16A3_LTR. We find that the expression of ERV3-16A3_LTR may itself be a negative prognostic biomarker in ccRCC. Our findings highlight the convergence of malignant epigenetic programs across ccRCC tumors and suggest that BAP1 loss, potentially through ERV3-16A3_LTR dysregulation, is associated with an IFN response-high epigenetic program.
- Open Access
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Patient demographic data for the female patients in the Extragonadal GCT cohort (both Make-an-IMPACT and internal MSK patients, n=16)
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Patient demographic data for the female patients in the Extragonadal GCT cohort (both Make-an-IMPACT and internal MSK patients, n=16)
- Open Access
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Clonality assessment of known oncogenic mutations in the female GCT cohort.
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Clonality assessment of known oncogenic mutations in the female GCT cohort.
- Open Access
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Genomically matched targeted therapies guided by MSK-IMPACT testing (n=22).
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Genomically matched targeted therapies guided by MSK-IMPACT testing (n=22).
- Open Access
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Patient demographic data for the female patients in the Extragonadal GCT cohort (both Make-an-IMPACT and internal MSK patients, n=16)
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Patient demographic data for the female patients in the Extragonadal GCT cohort (both Make-an-IMPACT and internal MSK patients, n=16)
- Open Access
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Genomically matched targeted therapies guided by MSK-IMPACT testing (n=22).
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Genomically matched targeted therapies guided by MSK-IMPACT testing (n=22).
- Open Access
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Clonality assessment of known oncogenic mutations in the female GCT cohort.
- 5 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Clonality assessment of known oncogenic mutations in the female GCT cohort.